

From Maria Caulfield MP Parliamentary Under-Secretary of State for Mental Health and Women's Health Strategy

> 39 Victoria Street London SW1H 0EU

PO-1501868

Dr Camilla Kingdon President, Royal College of Paediatrics and Child Health

Mr Henry Gregg Director of External Affairs, Asthma + Lung UK

By email to: bruce.warwick@rcpch.ac.uk

12 April 2024

Dear Dr Kingdon and Mr Gregg,

Thank you for your further correspondence of 18 March about the implementation of a respiratory syncytial virus (RSV) national vaccination programme.

I'm grateful to you for raising your concerns.

In my previous response, I noted that the Government recognises the potential seriousness of disease caused by RSV and acknowledges that it is a major cause of admissions to hospital and intensive care each winter.

As previously stated, officials across the Department, UK Health Security Agency and NHS England are continuing to develop options and plans based on the Joint Committee on Vaccination and Immunisation's advice regarding expanded RSV immunisation programmes to protect infants. NHS England continues to lead on delivery.

Following the closure of the Invitation to Offer period for RSV products on 29 February, a Full Business Case is being developed for Government consideration this spring. A final decision has yet to be taken on these programmes and any contract(s) would only be awarded if the Full Business Case is approved.

If any programmes are agreed to, their implementation will be announced in due course.

I hope this reply is helpful.

Yours sincerely.

MARIA CAULFIELD MP